Ann Parker

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

André T. Brunetto, Joo Ern Ang, Rohit Lal et al. · Clinical Cancer Research · 2013 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of concentration–response options for diacetyl in support of occupational risk assessment

Andrew Maier, Melissa Vincent, Ann Parker et al. · Regulatory Toxicology and Pharmacology · 2010 · 30 citations

Pharmacy, Risk Management, Occupational Health +13

Mode of action analysis for liver tumors from oral 1,4-dioxane exposures and evidence-based dose response assessment

Michael L. Dourson, John F. Reichard, Patricia Nance et al. · Regulatory Toxicology and Pharmacology · 2014 · 27 citations · Full text

Pharmacy, Oncology, Toxicology +17

Proposal of new uncertainty factor application to derive tolerable daily intake

Ryuichi Hasegawa, Mutsuko Hirata‐Koizumi, Michael L. Dourson et al. · Regulatory Toxicology and Pharmacology · 2010 · 24 citations

Agriculture, Nutrition, Nutritional Sciences +12

Derived Reference Doses (RfDs) for the environmental degradates of the herbicides alachlor and acetochlor: Results of an independent expert panel deliberation

Bernard Gadagbui, Andrew Maier, Michael L. Dourson et al. · Regulatory Toxicology and Pharmacology · 2010 · 19 citations

Natural Sciences, Environmental Sciences, Toxicology +17